22 studies found for:    brca | Open Studies | United States, Massachusetts
Show Display Options
Rank Status Study
1 Recruiting Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
2 Recruiting Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Conditions: Breast Cancer Metastatic;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: Olaparib;   Drug: Physician's choice chemotherapy
3 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
4 Recruiting Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
5 Recruiting The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Temozolomide;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
6 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
7 Recruiting Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: Advanced Malignant Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier
Interventions: Drug: Carboplatin;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
8 Recruiting A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Conditions: Carcinoma of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation
Interventions: Drug: niraparib;   Drug: Physician's choice
9 Recruiting Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Conditions: Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention;   Other: educational intervention;   Other: survey administration;   Behavioral: psychosocial assessment and care;   Behavioral: supportive care
10 Recruiting Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Condition: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: Drug: OLAPARIB;   Drug: Single agent chemotherapy
11 Recruiting Eribulin in HER2 Negative Metastatic BrCa
Condition: Breast Cancer
Intervention: Drug: Eribulin
12 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
13 Recruiting A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Placebo
14 Recruiting Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
Condition: Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Intervention:
15 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
16 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
17 Recruiting Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
18 Recruiting Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Conditions: Germline BRCA1/2 Mutations and;   Metastatic Adenocarcinoma of the Pancreas
Interventions: Drug: Olaparib;   Drug: Placebo
19 Recruiting HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Condition: Breast Cancer
Interventions: Drug: HKI-272;   Procedure: Surgical Resection;   Drug: Capecitabine
20 Recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Rucaparib

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years